- Conditions
- Friedreich Ataxia
- Interventions
- Buccal Swabs and Blood Draws
- Diagnostic Test
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 20 participants
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Pregnancy Following IVF With PGS/PGD
- Interventions
- Blood draw
- Procedure
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 275
- States / cities
- Birmingham, Alabama • Clovis, California • Concord, California + 195 more
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
- Interventions
- phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
- Interventions
- Continuous Glucose Monitoring with treatment algorithm
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Chapel Hill, North Carolina
- Conditions
- HIV
- Interventions
- Number of DBS Spots
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
- Interventions
- Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
- Conditions
- Anticoagulation and Thrombosis Point of Care Test (AT-POCT)
- Interventions
- Anticoagulation and Thrombosis Point of Care Test(AT-POCT), Duke Central Automated Laboratory (DCAL)
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Continuous Glucose Monitoring, Insulin Lispro
- Device · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Escondido, California • Los Angeles, California • Ventura, California + 3 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Plasma Cell Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 7
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more
- Conditions
- Prostate Carcinoma
- Interventions
- Behavioral Intervention, Biospecimen Collection, Electronic Health Record Review, Genetic Counseling, Genetic Testing, Interview, Survey Administration
- Behavioral · Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 44
- States / cities
- Duarte, California • Irvine, California • Orange, California + 35 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Osteoporosis
- Interventions
- Vital signs, Urine Pregnancy Test, Questionnaires, Blood Test, Duel-energy X-ray absorptiometry scan, Multi-detector computed tomography, Dual-energy X-ray absorptiometry scan
- Diagnostic Test · Other
- Lead sponsor
- Punam K Saha
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • New York, New York
- Conditions
- Hemophilia A
- Interventions
- Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 1 Year · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • New Brunswick, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- PRT064445/Apixaban, Placebo/Apixaban, Placebo
- Combination Product · Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
- Interventions
- Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram
- Diagnostic Test · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
- Device · Combination Product
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
- Conditions
- B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
- Interventions
- Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Years to 39 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
- Behavioral
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Interventions
- Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 323
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more